Resectable Hepatocellular Carcinoma Clinical Trials in Beijing, Beijing Municipality
3 recruitingBeijing, Beijing Municipality, China
Showing 1–3 of 3 trials
Recruiting
Phase 2
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled4 locationsNCT07239245
Recruiting
Phase 2
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Unresectable Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute111 enrolled1 locationNCT06360042
Recruiting
Phase 2
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
Unresectable Hepatocellular CarcinomaOligometastatic Disease
Peking University Cancer Hospital & Institute39 enrolled1 locationNCT05917431